• ERYtech Pharma Inc., of Lyon, France, completed enrollment and safety follow-up in a Phase II trial of GRASPA (encapsulated L-asparaginase in red blood cells) in first-line acute lymphoblastic leukemia in patients older than 55. The firm anticipates reporting data from the 30-patient study in the third quarter.